BUZZ — Citi lifts ResMed's ASX — listed stock's target price after FX, valuation updates
* Citi expects ResMed to report Q1 sales growth of 3.3%, including a 3% headwind from the absence of Astral ventilator sales and the impact of the MatrixCare divestment * Brokerage said it is broadly in line with consensus on revenue but about 2% below consensus on EPS due to a slightly lower gross margin forecast and